BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 17620860)

  • 1. The paradox of dysfunctional high-density lipoprotein.
    Ansell BJ; Fonarow GC; Fogelman AM
    Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the anti-inflammatory effects of high-density lipoprotein.
    Ansell BJ
    Am J Cardiol; 2007 Dec; 100(11 A):n3-9. PubMed ID: 18047850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-density lipoprotein function recent advances.
    Ansell BJ; Watson KE; Fogelman AM; Navab M; Fonarow GC
    J Am Coll Cardiol; 2005 Nov; 46(10):1792-8. PubMed ID: 16286161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple actions of high-density lipoprotein.
    Florentin M; Liberopoulos EN; Wierzbicki AS; Mikhailidis DP
    Curr Opin Cardiol; 2008 Jul; 23(4):370-8. PubMed ID: 18520722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
    Kontush A; Chapman MJ
    Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis.
    Carlquist J; Anderson JL
    Curr Opin Cardiol; 2007 Jul; 22(4):352-8. PubMed ID: 17556889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation, high-density lipoprotein and cardiovascular dysfunction.
    Haas MJ; Mooradian AD
    Curr Opin Infect Dis; 2011 Jun; 24(3):265-72. PubMed ID: 21326098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL function as a target of lipid-modifying therapy.
    Watson KE; Ansell BJ; Watson AD; Fonarow GC
    Rev Cardiovasc Med; 2007; 8(1):1-8. PubMed ID: 17401296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoprotein metabolism and endothelial function.
    Lowenstein CJ; Cameron SJ
    Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):166-70. PubMed ID: 20125006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density lipoprotein cholesterol-raising strategies.
    Kuvin JT; Alsheikh-Ali AA; Karas RH
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):196-204. PubMed ID: 16495756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoprotein and atheroma monitoring.
    Nicholls SJ; Tuzcu EM
    Curr Opin Cardiol; 2008 Jul; 23(4):386-92. PubMed ID: 18520724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.
    Nofer JR; Walter M; Assmann G
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1071-86. PubMed ID: 16292998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory investigation of dysfunctional HDL.
    Guo ZG; Li C; Zhong JK; Tu Y; Xie D
    Chem Phys Lipids; 2012 Jan; 165(1):32-7. PubMed ID: 22064068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High density lipoproteins (HDL). A therapeutic objective in the atherosclerosis prevention?].
    Pérez-Méndez O
    Arch Cardiol Mex; 2004; 74(1):53-67. PubMed ID: 15125268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids.
    Nofer JR; Assmann G
    Trends Cardiovasc Med; 2005 Oct; 15(7):265-71. PubMed ID: 16226682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics of high-density lipoproteins.
    Dastani Z; Engert JC; Genest J; Marcil M
    Curr Opin Cardiol; 2006 Jul; 21(4):329-35. PubMed ID: 16755202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.